Cyclophosphamide
Colon Disease
H. Lee Moffitt Cancer Center and Research InstituteSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Colon Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin H. Lee Moffitt Cancer Center and Research Institute | Phase 1/2 | CCC |
Ibrutinib H. Lee Moffitt Cancer Center and Research Institute | Phase 1/2 | CCC |
Pembrolizumab H. Lee Moffitt Cancer Center and Research Institute | Phase 1/2 | CCC |
Bisacodyl Parc Taulí Hospital Universitari | N/A | D |
MACROGOLS Eastern Mediterranean University | N/A | D |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →